March 17, 2023—Ichor Vascular, Inc. announced the submission of a 510(k) application for the company’s venous peripheral reperfusion system.
According to the company, the venous system is a compliment to the peripheral Ichor reperfusion system, which is 510(k)-cleared for clot removal in lower-extremity vascular disease.
Ichor Vascular’s percutaneous arterial and venous peripheral solutions are designed to remove vascular occlusions by using compliant mechanisms of action (vessel sweeping, aspiration, snaring) without the need of lytics or capital equipment.
Tim Blair, Ichor Vascular’s CEO noted in the press release, “Physicians will be able to treat large vessel and small vessel anatomy (2-18 mm) across a wide range of morphology from acute clot, acute-on-chronic clot, embolic material, to lengthy organized thrombus with a single device.”
The company stated that the Ichor vascular reperfusion system provides interventional versatility and ease of use that fit into current workflows and treatment algorithms for peripheral thrombectomy. Postmarket data will be focused on improving total time to reperfusion, reductions in blood loss compared to vacuum-pump based systems, reductions in distal embolization, eliminating vessel and valve damage, and reducing or eliminating surgical and drug complications by embracing a straightforward endovascular approach, advised the Ichor Vascular.
About iCHOR
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair. They identified an opportunity to develop new technologies to address these large unmet needs in treating peripheral vascular occlusions. This collaboration has lead to the development of the iSWEEP platform technology that has converted the tried and true Fogarty balloon sweep technique from an open surgery to a simple, minimally-invasive endovascular procedure.
For further information please contact:
Tim Blair
Chief Executive Officer
[email protected]
